[go: up one dir, main page]

MXPA06001110A - Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer. - Google Patents

Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer.

Info

Publication number
MXPA06001110A
MXPA06001110A MXPA06001110A MXPA06001110A MXPA06001110A MX PA06001110 A MXPA06001110 A MX PA06001110A MX PA06001110 A MXPA06001110 A MX PA06001110A MX PA06001110 A MXPA06001110 A MX PA06001110A MX PA06001110 A MXPA06001110 A MX PA06001110A
Authority
MX
Mexico
Prior art keywords
kinase inhibitor
cancer
inhibition
treatment
combination
Prior art date
Application number
MXPA06001110A
Other languages
English (en)
Inventor
Lee Martin Greenberger
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA06001110A publication Critical patent/MXPA06001110A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invencion describe combinaciones que comprenden un agente citotoxico y un inhibidor de cinasa EGFR y metodo para tratar o inhibir cancer en un mamifero que necesite del mismo el cual comprende administrar al mamifero una cantidad efectiva de un agente citotoxico y un inhibidor de cinasa EGFR.
MXPA06001110A 2003-08-01 2004-07-28 Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer. MXPA06001110A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49213203P 2003-08-01 2003-08-01
PCT/US2004/024478 WO2005018677A2 (en) 2003-08-01 2004-07-28 Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer

Publications (1)

Publication Number Publication Date
MXPA06001110A true MXPA06001110A (es) 2006-04-11

Family

ID=34215843

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06001110A MXPA06001110A (es) 2003-08-01 2004-07-28 Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer.

Country Status (19)

Country Link
US (1) US20050026933A1 (es)
EP (1) EP1648516A2 (es)
JP (1) JP2007501238A (es)
KR (1) KR20060054412A (es)
CN (1) CN1832757A (es)
AR (1) AR045179A1 (es)
AU (1) AU2004266572A1 (es)
BR (1) BRPI0413255A (es)
CA (1) CA2533126A1 (es)
CO (1) CO5640151A2 (es)
CR (1) CR8181A (es)
EC (1) ECSP066341A (es)
IL (1) IL173081A0 (es)
MX (1) MXPA06001110A (es)
NO (1) NO20060398L (es)
RU (1) RU2006106267A (es)
TW (1) TW200515910A (es)
WO (1) WO2005018677A2 (es)
ZA (1) ZA200600915B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04009472A (es) * 2002-03-29 2005-02-03 Exxonmobil Chem Patents Inc Preparacion de hidrocarburos alquilaromaticos y alquilaril sulfonatos.
US7425662B2 (en) * 2002-03-29 2008-09-16 Exxonmobil Chemical Patents Inc. Oligomerization of olefins
EP2439285B1 (en) 2004-03-31 2019-05-08 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
CN1968706A (zh) * 2004-06-03 2007-05-23 霍夫曼-拉罗奇有限公司 用顺铂和egfr－抑制剂治疗
KR100881043B1 (ko) * 2004-06-03 2009-01-30 에프. 호프만-라 로슈 아게 옥살리플라틴 및 ｅｇｆｒ­억제제로의 치료
RU2405566C9 (ru) 2005-02-03 2012-04-27 Дзе Дженерал Хоспитал Корпорейшн Способ лечения рака, устойчивого к гефитинибу
EP1874920A4 (en) 2005-04-05 2009-11-04 Cellpoint Diagnostics DEVICES AND METHOD FOR ENRICHING AND CHANGING CIRCULATING TUMOR CELLS AND OTHER PARTICLES
BRPI0610574A2 (pt) * 2005-04-14 2010-07-06 Wyeth Corp uso de um inibidor de quinase para receptor do fator de crescimento epidérmico (egfr) em pacientes resistentes a gefitinib
SG164368A1 (en) * 2005-07-18 2010-09-29 Bipar Sciences Inc Treatment of cancer
AU2006272343B2 (en) * 2005-07-21 2012-09-13 Nuvo Research Ag Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment.
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
JP2009538317A (ja) * 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
EP2038654A4 (en) * 2006-06-12 2010-08-11 Bipar Sciences Inc METHOD FOR THE TREATMENT OF DISEASES WITH PARP INHIBITORS
AU2007292306A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
AU2007292387A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
EP2068911A4 (en) * 2006-09-13 2011-08-03 Arca Biopharma Inc METHOD FOR THE TREATMENT OF CANCER
DE102007024470A1 (de) 2007-05-24 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
NZ586123A (en) * 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors
KR20100102609A (ko) * 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법
CA2708157A1 (en) * 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
EP2072502A1 (de) 2007-12-20 2009-06-24 Bayer Schering Pharma Aktiengesellschaft Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
DK2310011T3 (da) 2008-06-17 2013-10-14 Wyeth Llc Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
SG10202102855RA (en) * 2008-08-04 2021-05-28 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
CN105574346A (zh) * 2008-09-05 2016-05-11 新基阿维罗米克斯研究公司 多肽偶联物与不可逆抑制剂的设计方法和检测方法
JP5992325B2 (ja) 2009-04-06 2016-09-14 ワイス・エルエルシー 乳癌のための、ネラチニブを活用する治療計画
US9556426B2 (en) 2009-09-16 2017-01-31 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
CN102724962B (zh) 2009-11-09 2017-05-17 惠氏有限责任公司 包衣药物球状体及其用于消除或减少病症比如呕吐和腹泻的用途
CN102812167A (zh) 2009-12-30 2012-12-05 阿维拉制药公司 蛋白的配体-介导的共价修饰
CA2935392C (en) 2014-01-01 2022-07-26 Medivation Technologies, Inc. Amino pyridine derivatives for the treatment of conditions associated with excessive tgf.beta activity
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020245208A1 (en) 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6384051B1 (en) * 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
ATE370123T1 (de) * 2001-11-27 2007-09-15 Wyeth Corp 3-cyanochinoline als inhibitoren von egf-r- und her2-kinasen

Also Published As

Publication number Publication date
WO2005018677A3 (en) 2006-05-26
AR045179A1 (es) 2005-10-19
JP2007501238A (ja) 2007-01-25
WO2005018677A2 (en) 2005-03-03
RU2006106267A (ru) 2006-07-27
CO5640151A2 (es) 2006-05-31
EP1648516A2 (en) 2006-04-26
NO20060398L (no) 2006-02-28
ECSP066341A (es) 2006-08-30
KR20060054412A (ko) 2006-05-22
ZA200600915B (en) 2007-12-27
CR8181A (es) 2006-07-14
IL173081A0 (en) 2006-06-11
BRPI0413255A (pt) 2006-10-03
CN1832757A (zh) 2006-09-13
CA2533126A1 (en) 2005-03-03
TW200515910A (en) 2005-05-16
US20050026933A1 (en) 2005-02-03
AU2004266572A1 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
MXPA06001110A (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer.
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
SG148202A1 (en) Quinazolinone compounds as anticancer agents
MX2023015236A (es) Combinaciones farmaceuticas que comprenden un inhibidor de kras g12c y sus usos para el tratamiento de cancer.
TN2010000209A1 (en) Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
TW200604192A (en) Compounds and methods for inhibiting mitotic progression
WO2004043374A3 (en) Methods and compositions for treating cancer using proteasome inhibitors
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
EP1492487A4 (en) INHIBITORS OF MITOTIC KINESIN
TN2010000208A1 (en) Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
IL180137A0 (en) 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
BR0313081A (pt) Combinação de um inibidor de aromatase com um bisfosfanato
TW200718421A (en) Use of an epidermal growth factor receptor kinase inhibitor (EGFR) in gefitinib resistant patients
MXPA05011213A (es) Combinacion de un inhibidor de ciclooxigenasa-2 y un agente antineoplasico tipo alquilacion para tratamiento de neoplasia.
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
WO2007146375A3 (en) Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer
TW200642688A (en) New use of PDE7 inhibitors
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer
WO2007110705A3 (en) Macrolide as inhibitors of mhc class ii
WO2000074667A3 (en) Compositions active in telomere damage comprising a taxane and telomerase inhibitor
TW200614985A (en) Compositions for the treatment of inflammation and pain using a combination of an NSAID and LTB4 receptor antagonist

Legal Events

Date Code Title Description
FA Abandonment or withdrawal